Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

Kiora Pharmaceuticals (NASDAQ: KPRX) closed a private placement providing up to $24 million in gross proceeds, including $5.0 million upfront and up to $19 million via milestone-based warrants.

Rhea-AI Summary

Kiora Pharmaceuticals (NASDAQ: KPRX) closed a private placement providing up to $24 million in gross proceeds, including $5.0 million upfront and up to $19 million via milestone-based warrants. The transaction closed April 6, 2026 and was priced at-the-market under Nasdaq rules.

Each share (or pre-funded warrant) sold with four short-term Tranche A-1 warrants and one Tranche A-2 warrant at a combined purchase price of $2.543. All common warrants are immediately exercisable at $1.94, and the company will file a resale registration statement covering the issued securities.

Positive

• Upfront funding secured: $5.0 million
• Total potential capital of $24 million including warrants
• Warrants exercisable immediately at $1.94 per share
• Resale registration filing agreed to cover issued securities

Negative

• Potential dilution if up to $19 million of warrants are exercised
• Tranche A-1 warrants shorten to 30 days after strategic transaction
• Tranche A-2 warrants shorten to 30 days upon Phase 3 enrollment

Argus Apr 7 session

+6.93% close to close Open Argus

Details

News Market Reaction – KPRX

In the Apr 7 session, KPRX gained 6.93%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.9% in the session following this news. A strong positive reaction aligns with an ...

Analysis

The stock moved +6.9% in the session following this news. A strong positive reaction aligns with an announcement that secures up to $24 million in potential funding, extending financial flexibility around ongoing trials. However, new equity and warrant structures can introduce dilution over time. Past news for KPRX has sometimes seen muted or negative follow-through, so investors often watch how quickly warrants are exercised and whether capital accelerates clinical or partnering milestones.

Key Figures

Private placement size: $24 million Upfront funding: $5.0 million Milestone warrant proceeds: $19 million +5 more

Private placement size

$24 million

Total gross proceeds potential from private placement

Upfront funding

$5.0 million

Immediate gross proceeds from private placement

Milestone warrant proceeds

$19 million

Potential gross proceeds upon full warrant exercise

Purchase price per unit

$2.543

Combined price per share or pre-funded warrant plus accompanying warrants

Warrant exercise price

$1.94

Exercise price of Tranche A-1 and A-2 common warrants

Tranche A-1 term

9 months

Initial term for Tranche A-1 common warrants

Tranche A-2 term

4 years

Initial term for Tranche A-2 common warrants

Pre-funded warrant strike

$0.0001

Exercise price per pre-funded warrant

Historical Context

5 past events · Latest: Mar 25

5 events

1. Mar 25

   Earnings & pipeline

   24h Move

   -1.0%

   Full-year 2025 results and progress on two Phase 2 retinal trials.

2. Feb 19

   Conference appearance

   24h Move

   -1.4%

   Announcement of presentation at a major healthcare life sciences conference.

3. Jan 27

   Advisory board add

   24h Move

   -0.5%

   Retinal disease expert joined scientific advisory board to guide clinical strategy.

4. Dec 01

   Patent & trial

   24h Move

   -2.5%

   New U.S. patent for KIO-100 formulations and ongoing Phase 2 KLARITY enrollment.

5. Nov 07

   Earnings & trials

   24h Move

   +0.4%

   Q3 2025 results with active Phase 2 trials and cash runway into late 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, pre-funded warrant, common warrants, tranche a-1, +4 more

8 terms

private placement financial

"today announced that it has closed on a private placement providing up to $24 million"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrant financial

"each share of common stock, or pre-funded warrant in lieu thereof, was sold together with"

A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.

common warrants financial

"four accompanying short-term Tranche A-1 common warrants and one accompanying Tranche A-2 common warrant"

A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.

tranche a-1 financial

"four accompanying short-term Tranche A-1 common warrants and one accompanying Tranche A-2"

Tranche A-1 is a specific slice of a larger loan or bond issue that has its own payment terms and priority for getting paid back. Think of a multi-layered cake where A-1 is a top slice—it usually gets paid before lower slices, so it tends to carry lower risk and a lower interest rate; investors watch its terms to judge potential return, safety, and how quickly they will be repaid if money is tight.

tranche a-2 financial

"four accompanying short-term Tranche A-1 common warrants and one accompanying Tranche A-2 common warrant"

Tranche A-2 is a specific slice of a larger debt or security offering, like one labeled piece in a multi-part loan or bond package. Investors treat it as having its own interest rate, payment priority and risk profile—think of a layered cake where A-2 is one middle layer that gets paid after higher-priority slices but before lower-priority ones—so its characteristics affect expected return and loss exposure.

section 4(a)(2) regulatory

"made in a private placement under Section 4(a)(2) of the Securities Act of 1933"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

regulation d regulatory

"and/or Regulation D promulgated thereunder, and the securities have not been registered"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

registration statement regulatory

"The Company has agreed to file a registration statement with the Securities and Exchange Commission"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Sole investors are Perceptive Advisors (new) and ADAR1 Capital Management

Encinitas, California--(Newsfile Corp. - April 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (the "Company"), today announced that it has closed on a private placement providing up to $24 million in gross proceeds, consisting of $5.0 million in upfront funding and up to an additional $19 million upon the exercise of accompanying milestone-based warrants. The sole investors in the private placement are Perceptive Advisors and ADAR1 Capital Management. No placement agent was engaged in connection with the transaction. The private placement was priced at-the-market under Nasdaq rules. Kiora intends to use the upfront proceeds from the private placement to support general corporate purposes, including business operations, strategic business development activities, and ongoing research and development.

Under the terms of the agreement, each share of common stock, or pre-funded warrant in lieu thereof, was sold together with four accompanying short-term Tranche A-1 common warrants and one accompanying Tranche A-2 common warrant at a combined purchase price of $2.543 per share. The Tranche A-1 common warrants have an initial term of up to 9 months, which is reduced to 30 days upon Kiora executing a strategic transaction that materially expands the market opportunity of the Company's therapeutic assets. The Tranche A-2 common warrants have an initial term of up to 4 years, which is reduced to 30 days upon any Kiora assets completing enrollment in a Phase 3 clinical trial. All of the common warrants are immediately exercisable at a price of $1.94 per share, representing potential aggregate gross proceeds to the Company of up to approximately $19 million if exercised in full.

In lieu of shares of common stock, the investors also received pre-funded warrants at a combined purchase price of $2.543 per pre-funded warrant and accompanying common warrants, which equals the purchase price per share of common stock and accompanying common warrants less $0.0001, which is equal to the exercise price of each pre-funded warrant. The transaction closed on April 6, 2026.

The offer and sale of the foregoing securities was made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock sold in the private placement, as well as the shares of common stock issuable upon exercise of the warrants.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification of such securities under the securities laws of that jurisdiction. Any offering of the securities under the resale registration statement will be made only by means of a prospectus.

Blank Rome LLP served as legal advisors to Kiora for this transaction.

About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed initially for the treatment of retinitis pigmentosa, with potential to expand into choroideremia and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of macular edema due to retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the anticipated use of proceeds from the private placement, the anticipated filing of a resale registration statement, the potential for the common warrants to be accelerated upon achieving future milestones, and the potential to receive proceeds upon the exercise of common warrants. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2026 or described in Kiora's other public filings, including on Form 10-Q filed with the SEC on November 7, 2025. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.

Contacts:
Investors
Investors@kiorapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291307

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kiora Pharmaceuticals (KPRX) announce in the April 7, 2026 private placement?

Kiora closed a private placement raising up to $24 million, including $5.0 million upfront and up to $19 million via warrants. According to the company, the transaction closed April 6, 2026 and was priced at-the-market under Nasdaq rules.

How are the warrants structured in KPRX's private placement and what are their exercise terms?

Each share (or pre-funded warrant) was sold with four Tranche A-1 warrants and one Tranche A-2 warrant at $2.543 combined. According to the company, all common warrants are immediately exercisable at $1.94 per share.

How much immediate cash did Kiora (KPRX) receive from the private placement and planned use of proceeds?

Kiora received $5.0 million in upfront proceeds and may receive up to $19 million from warrant exercises. According to the company, funds will support general corporate purposes, business development, and ongoing R&D.

What triggers the shortened exercise windows for KPRX's Tranche A-1 and A-2 warrants?

Tranche A-1 warrants reduce to a 30-day term upon a strategic transaction materially expanding assets' market opportunity. According to the company, Tranche A-2 shortens to 30 days if any Kiora asset completes enrollment in a Phase 3 trial.

Will Kiora (KPRX) register the resale of securities issued in the private placement?

Yes. Kiora has agreed to file a resale registration statement covering the shares sold and shares issuable on warrant exercise. According to the company, the resale registration will enable public resale once effective.

Who were the investors and was a placement agent used in KPRX's financing?

The sole investors were Perceptive Advisors and ADAR1 Capital Management, and no placement agent was engaged. According to the company, the offering was conducted in a private placement under applicable Securities Act exemptions.